NeOnc Technologies Holdings Inc. (NTHI)
NTHI trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1979414/000182912626002860/0001829126-26-002860-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | NTHI on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0001979414 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $40K |
| Net income | -$62.1M |
| Operating income | -$58.2M |
| Net margin | -155404.4% |
| Operating margin | -145637.5% |
| Revenue growth | -51.8% |
| Cash | $59K |
| Total assets | $2.8M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 3275.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors raise substantial doubt regarding the Company's ability to continue as a going concern one year from the issuance date of this Form 10-Q." | 10-Q 2026-11-05 |
| Cash and burn | $6.2M cash; operating cash flow -$5.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 28,850,588 (2026-11-05); 19,474,303 a year earlier. | Cover page 2026-11-05 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 3 S-3/F-3 shelf filings; 6 424B5 takedowns, 2 at the market | Latest 2026-09-10 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | CBIZ CPAs P.C., Philadelphia, Pennsylvania, United States; changed auditors 1 time in 24 months | 8-K 4.01 2025-04-01 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $1.3M, sold $17K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$4.4M | -$5.1M | $6.2M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | $0 | -$14.2M | -$4.8M | $2.0M | No debt tags | Needs four quarters | 10-Q 2026-08-10 |
| Q1 2026 2026-03-31 | Not filed | -$8.8M | -$7.0M | $139K | No debt tags | Needs four quarters | 10-Q 2026-05-15 |
| Q4 2025 2025-12-31 | $0 | -$15.5M | -$3.6M | $59K | $6.0M | $40K | 10-K 2026-03-31 |
| Q3 2025 2025-09-30 | $0 | -$8.6M | -$5.8M | $1.5M | $4.7M | $60K | 10-Q 2025-11-14 |
| Q2 2025 2025-06-30 | $0 | -$5.7M | -$5.3M | $125K | No debt tags | $60K | 10-Q 2025-08-18 |
| Q1 2025 2025-03-31 | $40K | -$32.3M | -$5.7M | $5.4M | $11.4M | $80K | 10-Q 2026-05-15 |
| Q4 2024 2024-12-31 | $20K | -$2.3M | -$954K | $65K | $11.7M | $83K | 10-K 2026-03-31 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-09-10 |
| Latest annual report | 10-K/A | 2026-05-05 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEFA14A | 2026-06-23 |
Source: SEC EDGAR submissions feed, 215 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +40.7% |
| 1 month | +89.2% |
| 3 months | +53.0% |
| Year to date | -40.6% |
| 1 year | -45.3% |
| From 52-week high | -54.3% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CNTN | Canton Strategic Holdings Inc. | $1.64 | -4.09% | $130.7M |
| MENS | Jyong Biotech Ltd. | $1.77 | +0.57% | $134.6M |
| MSLE | Satellos Bioscience Inc. | $6.47 | -2.34% | $137.3M |
| ALXO | ALX Oncology Holdings Inc. | $1.00 | -3.85% | $124.9M |
| AKBA | Akebia Therapeutics Inc. | $0.4486 | -5.40% | $124.6M |
| MGNX | MacroGenics Inc. | $2.17 | -1.36% | $138.7M |
| RNA | Atrium Therapeutics Inc. | $6.43 | -14.38% | $138.7M |
| SION | Sionna Therapeutics Inc. | $3.12 | -6.31% | $141.1M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier